Pharmacological efficacy and safety profile of taranabant in preclinical species
Authors:
- 22 June 2009
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 70 (5) , 349-362
Abstract
Taranabant is a highly selective and potent cannabinoid CB1receptor inverse agonist. We compared the pharmacological properties of taranabant with another inverse agonist, rimonabant, and determined the preclinical safety margins of taranabant. In vitro studies demonstrated that taranabant is ∼10‐fold more potent than rimonabant at the CB1receptor, and taranabant is more selective based on off‐target in vitro screening. In vivo efficacy studies demonstrated that taranabant is ∼10‐fold more potent than rimonabant in diet‐induced obese rats. In repeat‐dose toxicological studies, taranabant did not cause mortality in rodents and monkeys at exposure margins ≤6478 and 1922 times the estimated human exposure at 0.5 mg/day−1. Taranabant did not produce CNS signs, including seizures, when administered to monkeys for 1 year at 10 mg/kg−1day−1(highest dose tested chronically), corresponding to an exposure margin of 974 times. In contrast to primates, taranabant produced brief handling‐induced seizure‐like activity in rodents, species predisposed to handling‐induced seizures. Throughout the entire preclinical program, taranabant did not cause histopathological changes in the peripheral or central nervous system. In summary, the highly selective nature of taranabant is consistent with its generally favorable preclinical safety profile. Drug Dev Res 2009.Keywords
This publication has 35 references indexed in Scilit:
- Multiple‐Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 2008
- The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric IntakeCell Metabolism, 2008
- A neutral CB1 receptor antagonist reduces weight gain in ratAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- [18F]MK-9470, a positron emission tomography (PET) tracer forin vivohuman PET brain imaging of the cannabinoid-1 receptorProceedings of the National Academy of Sciences, 2007
- Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with DyslipidemiaNew England Journal of Medicine, 2005
- The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesisJournal of Clinical Investigation, 2003
- Leptin-regulated endocannabinoids are involved in maintaining food intakeNature, 2001
- Cannabinoids Modulate Synaptic Strength and Plasticity at Glutamatergic Synapses of Rat Prefrontal Cortex Pyramidal NeuronsJournal of Neurophysiology, 2000
- Appetite suppression and weight loss after the cannabinoid antagonist SR 141716Life Sciences, 1998
- A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1Journal of Biological Chemistry, 1997